SpliSense Raises $28.5M to Advance Treatments for Rare CF Mutations

SpliSense Raises $28.5M to Advance Treatments for Rare CF Mutations

294539

SpliSense Raises $28.5M to Advance Treatments for Rare CF Mutations

SpliSense has raised $28.5 million in funding to advance its antisense oligonucleotide (ASO) platform for the treatment of cystic fibrosis (CF) caused by certain rare mutations, and of other genetic lung diseases. ASOs are molecules designed to target the messenger RNA (mRNA), the intermediate molecule derived from DNA that guides protein production. Money raised came through a series B financing round featuring Orbimed, Israel Biotech Fund, Biotel Limited, Integra Holdings, and the Cystic Fibrosis Foundation (CFF). The CFF invested up to…

You must be logged in to read/download the full post.